Are targeted therapies a consideration in poorly differentiated neuroendocrine tumors?
Department of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Steven
S
Sorscher
D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic